Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology.

Abstract:

:Radiotherapy is a widely used local and regional modality for the treatment of cancer. Despite improved methods of radiation delivery, local recurrence accounts for treatment failure in most patients. Radiosensitizers have been studied as one approach for improving the effectiveness of radiotherapy. Few agents, however, have been shown to selectively increase the anti-tumor effects of radiation. Advances in our understanding of how cells respond molecularly to ionizing radiation have provided opportunities for the development of new approaches that selectively enhance radiotherapy of tumors. Cells respond to ionizing radiation with the activation of specific early and later response genes. These findings led us to the concept that promoters from these genes could be used to drive therapeutic transgenes introduced into irradiated tumor cells. In this strategy, designated genetic radiotherapy, radiation is combined with gene therapy, another local/regional modality, to spatially and temporally control transgene expression in the irradiated field. Tumor necrosis factor-alpha (TNF-alpha) was selected as the transgenic protein for its potent anti-tumor activity and synergistic interactions with ionizing radiation. The radio-inducible elements from the early growth response-1 (EGR-1) gene promoter have been inserted upstream to a cDNA encoding TNF-alpha and integrated into a replication-defective adenovirus (Ad.EGR-TNF). Preclinical studies have shown that tumors infected with Ad.EGR-TNF respond to radiation with induction of TNF-alpha expression and substantial increases in anti-tumor activity. Importantly, local production of TNF-alpha is not associated with the limiting toxicities encountered when this cytokine was administered systemically. Based on these findings, radiation in combination with intratumoral administration of a second generation Ad.EGR-TNF (TNFerade) has completed Phase I evaluation and has entered Phase II clinical trials.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Kufe D,Weichselbaum R

doi

10.4161/cbt.2.4.495

keywords:

subject

Has Abstract

pub_date

2003-07-01 00:00:00

pages

326-9

issue

4

eissn

1538-4047

issn

1555-8576

pii

495

journal_volume

2

pub_type

杂志文章,评审
  • Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

    abstract::There is an urgent need to develop new strategies to treat ovarian cancer, the most deadly gynecologic malignancy. Histone deacetylase (HDAC) inhibitors are emerging as novel therapeutic drugs in the treatment of a variety of cancers, including those resistant to standard chemotherapy. Since there are multiple HDAC is...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.5.4007

    authors: Khabele D,Son DS,Parl AK,Goldberg GL,Augenlicht LH,Mariadason JM,Rice VM

    更新日期:2007-05-01 00:00:00

  • The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer.

    abstract:OBJECTIVE:Angiogenesis is one of the key processes in the development of malignant tumors. The vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) signaling pathway regulates branching angiogenesis in cancer. In this study, we analyzed the associations of VEGF/VEGFR-2 proteins and VEGFR-2 genetic va...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1537575

    authors: Zhu X,Wang Y,Xue W,Wang R,Wang L,Zhu ML,Zheng L

    更新日期:2019-01-01 00:00:00

  • Genomic instability is associated with lack of telomerase activation in ovarian cancer.

    abstract:INTRODUCTION:Malignant cells are capable of an unlimited number of cell divisions, either through production of telomerase, or through the alternate lengthening of telomere (ALT) mechanism. Yeast cells with genomic instability have been shown to survive in the absence of telomerase by increased recombination events. We...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.12.1235

    authors: Landen CN,Klingelhutz A,Coffin JE,Sorosky JI,Sood AK

    更新日期:2004-12-01 00:00:00

  • Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.

    abstract::bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission. In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphat...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.10.17674

    authors: Tao K,Li YJ,Wang D,Qi JY,Deng YP,Wang HX,Hu J,Feng WL

    更新日期:2011-11-15 00:00:00

  • DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

    abstract::Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.972183

    authors: Yu R,Albarenque SM,Cool RH,Quax WJ,Mohr A,Zwacka RM

    更新日期:2014-01-01 00:00:00

  • Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice.

    abstract::We previously reported that the mutant virus of HSV (mtHSV) mediated tumor therapy was efficacious in Balb/c and nude mice. However, it is significant to know whether mtHSV works in HSV-1 tumor seropositive individuals because many patients with HSV-1 seropositivity have been found in clinical trial. Here we asked whe...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.5.3953

    authors: Zhu H,Su Y,Zhou S,Xiao W,Ling W,Hu B,Liu Y,Qi Y

    更新日期:2007-05-01 00:00:00

  • Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is important in nasopharyngeal carcinoma (NPC) pathogenesis. Activated PI3K and its downstream target Akt are concernful signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis and oncogenesis. The protein kinase A...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.4.7433

    authors: Yang L,Xiao L,Ma X,Tang M,Weng X,Chen X,Sun L,Cao Y

    更新日期:2009-02-01 00:00:00

  • In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter.

    abstract::To establish stable and long-term gene expression in vitro and in vivo, we developed a lentiviral vector system carrying sodium iodide symporter (hNIS) gene under UbC promoter, and transfected this into a colon cancer cell line. The in vitro and in vivo kinetics of radioiodine and [99mTc]-pertechnetate were then inves...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.7.4342

    authors: Kim HJ,Jeon YH,Kang JH,Lee YJ,Kim KI,Chung HK,Jeong JM,Lee DS,Lee MC,Chung JK

    更新日期:2007-07-01 00:00:00

  • Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

    abstract::The synergistic effect of combined drug therapy provides an enhanced treatment for advanced liver cancer. We aimed to investigate the underlying mechanism of cetuximab sensitization by rapamycin in hepatoma cells. Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29113

    authors: Chen W,Hu QD,Xia XF,Liang C,Liu H,Zhang Q,Ma T,Liang F,Liang TB

    更新日期:2014-08-01 00:00:00

  • Colorectal cancer: new advances in immunotherapy.

    abstract::Colorectal cancer remains the second leading cause of cancer-related mortality in the United States. Although surgical resection is still the primary treatment for colorectal cancer, in recent years, there has been a remarkable progress in the development of new therapies to treat colorectal cancer. Response rates hav...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.6.1.3672

    authors: Cubas R,Li M,Chen C,Yao Q

    更新日期:2007-01-01 00:00:00

  • Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells.

    abstract::Small-molecule inhibitors of cyclin-dependent kinases (CDKs) are known to induce cell cycle arrest and apoptosis in certain cancer cells. In order to evaluate the antitumor activity of one such inhibitor, GW8510, against human lung cancers, we analyzed the effects of GW8510 on six nonsmall cell lung cancer (NSCLC) cel...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.2.2316

    authors: Dong F,Guo W,Zhang L,Wu S,Teraishi F,Davis JJ,Fang B

    更新日期:2006-02-01 00:00:00

  • The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.

    abstract::The small GTPase Rac1 regulates many cellular processes, including cytoskeletal reorganization, cell migration, proliferation, and survival. Additionally, Rac1 plays a major role in activating NF-κB-mediated transcription. Both Rac1 and NF-κB regulate many properties of the malignant phenotype, including anchorage-ind...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20082

    authors: Gastonguay A,Berg T,Hauser AD,Schuld N,Lorimer E,Williams CL

    更新日期:2012-06-01 00:00:00

  • E2F1 as a target: promoter-driven suicide and small molecule modulators.

    abstract::Decreased requirements for mitogens and diminished sensitivity to antiproliferative signals are among the hallmarks of human cancer. These attributes are due, at least partly, to mutations that directly or indirectly compromise the function of the retinoblastoma tumor suppressor protein (pRB), which is a negative regu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Kaelin WG Jr

    更新日期:2003-07-01 00:00:00

  • Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction.

    abstract::Phorbol 12-myristate 13-acetate (PMA) modulates cell proliferation and survival by activating several intracellular signaling pathways. Protein kinase C (PKC) plays a key role in PMA-induced growth arrest of non-small cell lung cancer (NSCLC) cells. Kruppel-like transcription factor 6 (KLF6), which is associated with ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.9.8186

    authors: Tahara E,Kadara H,Lacroix L,Lotan D,Lotan R

    更新日期:2009-05-01 00:00:00

  • Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis.

    abstract::Head and neck squamous cell carcinoma (HNSCC) remains a significant cause of morbidity and mortality. There has been a great interest in finding specific genomic changes which contribute to HNSCC tumorigenesis, especially within the chromosome 3p area, where high frequency of LOH (loss of heterozygosity) has been repo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.7.12886

    authors: Lee DJ,Schönleben F,Banuchi VE,Qiu W,Close LG,Assaad AM,Su GH

    更新日期:2010-10-01 00:00:00

  • Epigenetic changes in gliomas.

    abstract::Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence. While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells. In this r...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.7.9.6992

    authors: Burgess R,Jenkins R,Zhang Z

    更新日期:2008-09-01 00:00:00

  • The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status.

    abstract::Metastatic cervical cancer remains a clinical problem. The development of more efficient treatment modalities and the optimal use of chemo- and radiotherapy require better understanding of their impact on regulation of cell survival and apoptosis, but the issue is insufficiently explored. Human papillomavirus (HPV) E6...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.11.1340

    authors: Koivusalo R,Hietanen S

    更新日期:2004-11-01 00:00:00

  • Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN).

    abstract:OBJECTIVES:The biochemical response of prostatic cells to needle core biopsies is known to manifest as a rise in serum PSA. The aim of this study is to evaluate the PSA response to mechanical trauma in prostate cancer patients, when compared to benign controls. MATERIALS AND METHODS:50 consecutive patients undergoing ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.181

    authors: Bhanot S,Gopalakrishnan R,Oliver RT

    更新日期:2003-01-01 00:00:00

  • Furanodiene induces G2/M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells.

    abstract::Furanodiene (C15H20O), a pure compound isolated from Traditional Chinese medicine, Curcuma wenyujin, named Ezhu in Chinese, which structure was determined on the basis of NMR, MS and UV spectrum. In this study, we attempted to characterize in detail the signaling cascades resulted from furanodiene-induced apoptosis in...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.7.4317

    authors: Xiao Y,Yang FQ,Li SP,Gao JL,Hu G,Lao SC,Conceição EL,Fung KP,Wangl YT,Lee SM

    更新日期:2007-07-01 00:00:00

  • Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.

    abstract::Cytotoxic chemotherapeutic drugs, especially when used in combination, are widely employed to treat a variety of cancers in patients but often lead to serious symptoms that negatively affect physical functioning and quality of life. There is compelling evidence that implicates cytotoxic chemotherapy-induced inflammati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29922

    authors: Wong J,Tran LT,Magun EA,Magun BE,Wood LJ

    更新日期:2014-10-01 00:00:00

  • MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

    abstract::Clear cell RCC is the most common, and more likely to metastasize, of the three main histological types of RCC. Pathologic stage is the most important prognostic indicator and nuclear grade can predict outcome within stages of localized RCC. Epithelial tumors are thought to accumulate a series of genetic and epigeneti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27314

    authors: Gowrishankar B,Ibragimova I,Zhou Y,Slifker MJ,Devarajan K,Al-Saleem T,Uzzo RG,Cairns P

    更新日期:2014-03-01 00:00:00

  • Ras family signaling: therapeutic targeting.

    abstract::Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.306

    authors: Cox AD,Der CJ

    更新日期:2002-11-01 00:00:00

  • Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.

    abstract::Aggressive fibromatosis (AF) or desmoid tumors is an aggressive fibroblastic proliferation which is locally invasive but can not metastasize. The treatment of AF is challenging. Surgery was the main treatment modality for AF in the past, other strategies including radiotherapy, systemic therapies and wait-and-see poli...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1373215

    authors: Yang S,Wang X,Jiang H,Wang Y,Li Z,Lu H

    更新日期:2017-10-03 00:00:00

  • Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice.

    abstract::Endostatin can inhibit tumor growth by blocking angiogenesis, whereas tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill cancer cells without toxicity to most normal cells. To establish the combined anti-tumor therapeutic effect of endostatin and solu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.5.7687

    authors: Zhang Y,Qu ZH,Cui M,Guo C,Zhang XM,Ma CH,Sun WS

    更新日期:2009-03-01 00:00:00

  • The molecular pathogenesis of head and neck cancer.

    abstract::Head and neck cancer arises from a series of molecular alterations progressive from dysplasia to carcinoma in situ, and finally invasive carcinoma. Risk factors associated with head and neck cancer include tobacco, alcohol and viral infection. There are genetic alterations in pre-cancerous cells that contribute to tra...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.9.1.10905

    authors: Klein JD,Grandis JR

    更新日期:2010-01-01 00:00:00

  • Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.

    abstract::Celecoxib exhibits cancer preventive and therapeutic effects in animal models and clinical trials. It presumably acts through selective inhibition of cyclooxygenase-2 (COX-2) and subsequent reduction of prostaglandin (PG) synthesis. However, the concentrations of celecoxib required for growth inhibition and apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1618

    authors: Sun SY,Schroeder CP,Yue P,Lotan D,Hong WK,Lotan R

    更新日期:2005-04-01 00:00:00

  • Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

    abstract::Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 kinase (PI3K)/Akt/mam...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26725

    authors: Okabe S,Tauchi T,Tanaka Y,Kitahara T,Kimura S,Maekawa T,Ohyashiki K

    更新日期:2014-02-01 00:00:00

  • Randomized discontinuation trial of sorafenib (BAY 43-9006).

    abstract::With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/cbt.5.10.3290

    authors: Jain L,Venitz J,Figg WD

    更新日期:2006-10-01 00:00:00

  • Knockdown of ezrin via RNA interference suppresses Helicobacter pylori-enhanced invasion of gastric cancer cells.

    abstract:BACKGROUND AND AIM:H. pylori interacts with gastric epithelial cells, which may activate signaling pathways important for gastric cancer invasion. Ezrin, a membrane cytoskeletal crosslinker protein, is well documented to regulate cell adhesion and cell motility. The aim of the present study was to determine whether ezr...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.8.14691

    authors: Fan LL,Chen DF,Lan CH,Liu KY,Fang DC

    更新日期:2011-04-15 00:00:00

  • A novel bispecific antibody, BiSS, with potent anti-cancer activities.

    abstract::One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody wit...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139266

    authors: Dong B,Zhou C,He P,Li J,Chen S,Miao J,Li Q,Wang Z

    更新日期:2016-04-02 00:00:00